Effects of antimicrobial peptide from lactoferrin in blood serum and urine in patients with renal colica with urolithiasis and pyelonephritis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To evaluate the role of lactoferrin and lactoferricin in blood serum and urine in patients with an attack of renal colic against the background of urolithiasis and pyelonephritis.

Materials and methods. We examined 149 patients admitted to the urological department of the City Clinical Hospital No. 3 of Astrakhan, according to emergency indications, with an attack of renal colic. Along with standard clinical, laboratory and instrumental research methods (general blood count, biochemical blood test, urinalysis, kidney ultrasonography), the concentration of CRP and lactoferrin was measured in all patients in the blood and urine using a set of reagents for ELISA (Lactoferrin «Vector-Best» Novosibirsk city). The sensitivity of the test for CRP and LF was 3–5 µg/ml and 5 ng/ml, respectively. Studies of all collected material for lactoferricin were carried out deferred in the laboratory of the Astrakhan State Medical University. Based on the results of clinical and instrumental studies, patients admitted with an attack of renal colic were retrospectively divided into three groups: the first group included 38 patients with urolithiasis. The second group included 64 patients with obstructive pyelonephritis, and the third group included 47 patients hospitalized with characteristic signs of primary non-obstructive pyelonephritis. The groups were matched by sex and age. Blood and urine samples from 25 donors served as controls.

Results. When comparing a group of patients with urolithiasis with a group of patients with non-obstructive and obstructive pyelonephritis, highly significant differences (p<0.0001) were found in LF, LFC, CRP and the number of leukocytes in the blood and urine sediment. In urine, according to the results of ROC-analysis in couples with urolithiasis without pyelonephritis in comparison with obstructive pyelonephritis, the most significant differences were established for all four parameters studied: for LF (AUC=0.823), for LFC (AUC=0.832), for CRP (AUC=0.829 ) and the number of leukocytes in the urine sediment (AUC=0.780).

Discussion. In blood and urine in patients with urolithiasis and pyelonephritis, the effects of the bactericidal peptide LPC were compared with the levels in biological fluids of CRP, LF, and the number of leukocytes. The greatest diagnostic value of all four studied indicators was found in urine, and not in serum. ROC-analysis confirmed a more significant effect of the studied parameters on pyelonephritis than on urolithiasis. The level of lactoferrin and CRP in patients at admission correlates with the number of leukocytes in the blood and urine sediment and with the degree of inflammation in the body. And the level of LFC peptide in the urine reflects the degree of infection of the urinary tract.

Conclusions. A comparative study of tests for Lf and LFC in blood serum and urine in patients admitted to a urological hospital with an attack of renal colic was carried out. Determining the concentration of lactoferricin in the urine is an informative indicator. Thus, lactoferrin and its hydrolysis product lactoferricin reflect different aspects of the infectious and inflammatory process in pyelonephritis.

Full Text

Restricted Access

About the authors

A. A. Serebryakov

Clinical Hospital, No. 3

Author for correspondence.
Email: serebryakov30@mail.ru

urologist

Russian Federation, Astrakhan

V. M. Miroshnikov

Astrakhan State Medical University, Ministry of Health of the Russian Federation

Email: miroshnikov-valentin@mail.ru

Doctor of Medical Sciences, Professor, Professor of the Department of Urology

Russian Federation, Astrakhan

A. V. Kokhanov

Astrakhan State Medical University, Ministry of Health of the Russian Federation

Email: dogma190799@gmail.com

Doctor of Medical Sciences, Professor, Professor of the Department of Chemistry

Russian Federation, Astrakhan

A. O. Dogadina

Astrakhan State Medical University, Ministry of Health of the Russian Federation

Email: dogma190799@gmail.com

6th year student

Russian Federation, Astrakhan

K. N. Mekhtiev

Astrakhan State Medical University, Ministry of Health of the Russian Federation

Email: kmager78@gmail.com

6th year student

Russian Federation, Astrakhan

References

  1. Lopatkin N.A., Kamalov A.A., Apolikhin O.I. et al. Urology. Moscow: GEOTAR-Media, 2013; 816 р. Russian (Лопаткин Н.А., Камалов А.А., Аполихин О.И. и др. Урология. М.: ГЭОТАР-Медиа, 2013; 816 с.).
  2. Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu. Urology. Russian clinical guidelines. Moscow: GEOTAR-Media, 2015; 480 р. Russian (Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Российские клинические рекомендации. М.: ГЭОТАРМедиа, 2015; 480 с.).
  3. Sigitova O.N., Bogdanova A.R. Sovremennye podhody k diagnostike, klassifikacii i ocenke tjazhesti ostrogo povrezhdenija pochek. Vestnik sovremennoj klinicheskoj mediciny. 2015;1. Russian. (Сигитова О.Н., Богданова А.Р. Современные подходы к диагностике, классификации и оценке тяжести острого повреждения почек. Вестник современной клинической медицины. 2015;1).
  4. Tandogdu Z., Cek M., Wagenlehner F. et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J. Urol. 2014;32(3):791–801.
  5. Vesnina Zh.V. New and potential biomarkers of acute kidney damage. Clinical laboratory diagnostics. 2018;63(7):388–396. Russian (Веснина Ж.В. Новые и потенциальные биомаркёры острого повреждения почек. Клиническая лабораторная диагностика. 2018;63(7):388–396.
  6. Zakharova I.N., Osmanov I.M., Klimov L.Ya., Kasyanova A.N., Kuryaninova V.A., Lupan I.N. The role of antimicrobial peptides in defending the urinary tract against infections. Meditsinsky Sovet. 2019;2:143–150. doi: 10.21518/2079-701X-2019-2-143-150. Russian. (Захарова И.Н., Османов И.М., Климов Л.Я., Касьянова А.Н., Курьянинова В.А., Лупан И.Н. Роль антимикробных пептидов в защите от инфекций мочевых путей. Медицинский совет. 2019;2:143–150. doi: 10.21518/2079-701X-2019-2-143-150).
  7. Spencer J.D., Schwaderer A.L., Becknell B., Watson J., Hains D.S. The innate immune response during urinary tract infection and pyelonephritis Pediatr. Nephrol. 2014;29(7):1139–1149.
  8. Mayeur S., Spahis S., Pouliot Y., Levy E. Lactoferrin, a pleiotropic protein in health and disease. Antioxid. Redox Signal. 2016;24:813–836. doi: 10.1089/ars.2015.6458.
  9. Serebryakov A.A., Kokhanov A.V., Nikolaev A.A. Uroproteins with antibacterial proprieties: value for clinic and diagnostic. Astrakhan Medical Journal. 2020; 15(3):32-47. Russian. (Серебряков А.А., Коханов А.В., Николаев А.А. Уропротеины с антибактериальными свойствами: клинико-диагностическое значение. Астраханский медицинский журнал. 2020; 15(3):32–47).
  10. Aleshina G.M. Lactoferrin – an endogenous regulator of the protective functions of the organism. Medical Academic Journal. 2019;19(1):35–44. doi: 10.17816/MAJ19135-144. Russian. (Алешина Г.М. Лактоферрин – эндогенный регулятор защитных функций организма. Медицинский академический журнал. 2019;19(1):35–44. Doi: 10.17816/ MAJ19135–44.
  11. Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol. 2012;90(3):252–268. doi: 10.1139/o11-056.
  12. Drago-Serrano M.E., Campos-Rodriguez R., Carrero J.C., de la Garza M. Lactoferrin and peptidederivatives: antimicrobial agents with potential use in nonspecific immunity modulation. Curr. Pharm. Des. 2018;24(10):1067–1078. doi: 10.2174/1381612824666180327155929.
  13. Patras K.A., Ha A.D., Rooholfada E. et al. Augmentation of urinary lactoferrin enhances host innate immune clearance of uropathogenic Escherichia coli. Infect Immun 2000;68:5816–5823.
  14. Pierce A., Legrand D., Mazurier J. Lactoferrin: a multifunctional protein. Review. French. Med Sci (Paris). 2009;25(4):361–369. doi: 10.1051/medsci/ 2009254361.
  15. Sadchikov P.E., Gol’dman I.L., Namazova-Baranova L.S., Yatsyk G.V., Borovik T.E., Chernousov A.D., Romanchenko A.I., Sadchikova E.R., Lukoyanova O.L., Zvonkova N.G., Belyaeva I.A. Lactoferrin in the problem of anti-infective protection of children in the first year of life. Pediatricheskaya farmakologiya – Pediatric Pharmacology. 2016;13(6):607–613. Russian. doi: 10.15690/pf.v13i6.1677 (Садчиков П.Е., Гольдман И.Л., Намазова-Баранова Л.С., Яцык Г.В., Боровик Т.Э., Черноусов А.Д., Романченко А.И., Садчикова Е.Р., Лукоянова О.Л., Звонкова Н.Г., Беляева И.А. Лактоферрин в проблеме противоинфекционной защиты детей первого года жизни. Педиатрическая фармакология. 2016;13(6):607–613. doi: 10.15690/pf.v13i6.1677).
  16. Arias M., McDonald L.J., Haney E.F., Nazmi K., Bolscher J.G., Vogel H.J. Bovine and human lactoferricin peptides: chimeras and new cyclic analogs. Biometals. 2014;27(5):935–948. doi: 10.1007/s10534-014-9753-4.
  17. Silva T., Magalhães B., Maia S., Gomes P., Nazmi K., Bolscher J.G.M., Rodrigues P.N., Bastos M., Gomesa M.S. Killing of Mycobacterium avium by lactoferricin peptides: improved activity of arginine- and d-amino-acid-containing molecules. Antimicrobial Agents and Chemotherapy. 2014;5(6): 3461–3467.
  18. Zasloff M. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J. Am.Soc.Nephrol. 2007;18(11):2810–2816.
  19. Duke V.A., Emanuel V.L. Information technologies in biomedical research. St. Petersburg: Piter. 2003:525. Russian. (Дюк В.А., Эмануэль В.Л. Информационные технологии в медико-биологических исследованиях. СПб.: Питер. 2003:525).
  20. Krutikov E.S., Zhitova V.A. Factors of immune protection in the pathogenesis of urinary infections (literature review). Nephrology. 2020; 24(5):9–17. doi: 10.36485/1561-6274-2020-24-5-9-17. Russian (Крутиков Е.С., Житова В.А. Факторы иммунной защиты в патогенезе инфекций мочевыводящих путей (обзор литературы). Нефрология. 2020;24(5):9–17. doi: 10.36485/1561-6274-2020-24-5-9-17).
  21. Masajtis-Zagajewska A, Nowicki M. New markers of urinary tract infection. Clin Chim Acta. 2017;471:286–291. doi: 10.1016/j.cca.2017.06.003
  22. Malaeva E.G. Urinary lactoferrin level in patients with liver cirrhosis and urinary tract infection. Lechebnoye delo – Medical business. 2013;4(24):50–53. www.lech-delo.by Russian. (Малаева Е.Г. Уровень лактоферрина в моче у пациентов c циррозом печени и инфекцией мочевых путей. Лечебное дело. 2013;4(24):50–53. www.lech-delo.by).
  23. Antonov A.G., Godin M.K. Renal tissue damage markers in urolithiasis complicated by pyelonephritis. Far eastern medical journal. 2017;2:93–98. Russian (Антонов А.Г., Годин М.К. Возможности использования маркеров воспаления при мочекаменной болезни, осложненной пиелонефритом. Дальневосточный медицинский журнал. 2017;2:93–98).
  24. Kokhanov A.V., Lutseva O.A., Serebryakov A.A., Golubkina S.A. A method for diagnosing acute appendicitis with clinical symptoms simulating right-sided renal colic. Patent for invention No. 2684727 (Коханов А.В., Луцева О.А., Серебряков А.А. Голубкина С.А. Способ диагностики острого аппендицита с клинической симптоматикой, имитирующей правостороннюю почечную колику. Патент на изобретение № 2684727).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies